Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2 negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: a pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials
国際学会発表
A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601)
Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy（OGSG1201）
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy (OGSG1201)
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus platinum (OGSG0701)
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 in patients with advanced gastric cancer refractory to S-1 or S-1 plus CDDP（OGSG0701）
A Phase I/II Trial of Radiotherapy Concurrent with TS-1 Plus Cisplatin in Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group（OGSG1205）
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer ; OGSG1101, HGCSG1102, T-CORE1101 Intergroup study (HERBIS-1 trial)